New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTATHX, CYTX, NBS, CAPR, PBMD, CELG, HART, BLUE, FATEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
News For BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
08:14 EDTCYTXCytori Therapeutics says company-supported trial in Japan to begin enrollment
Subscribe for More Information
July 29, 2015
20:10 EDTCELGCelgene says patent challenges are baseless, Reuters reports
Subscribe for More Information
July 28, 2015
09:18 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTCYTXCytori licensee Kerastem receives conditional FDA approval for alopecia trial
Cytori Therapeutics announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. FDA conditional Investigational Device Exemption approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness.The phase II study, known as the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the FDA IDE submission. The data will be presented in September at the 2015 International Society of Hair Restoration Surgery meeting in Chicago. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centers within the United States. The primary endpoint is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density. In 2013, Bimini, a private medical technology company, acquired global and exclusive rights to commercialize Cytori Celution Technology for alopecia and hair related indications. Under the commercial agreement, Bimini will be responsible for all key activities including clinical studies, regulatory approvals, and market development. Bimini will acquire Cytori products at agreed upon transfer pricing and pay Cytori a perpetual royalty on sales.
07:31 EDTCELGCelgene commences tender offer for Receptos
Subscribe for More Information
July 27, 2015
10:40 EDTCELG, BLUEIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
08:38 EDTCELGAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
July 24, 2015
08:08 EDTCELGCelgene price target raised to $190 from $156 at Canaccord
Subscribe for More Information
July 23, 2015
19:50 EDTCELGCelgene price target raised to $163 from $146 at Cantor
Subscribe for More Information
10:50 EDTCELGCelgene positioned for sustainable growth, says Piper Jaffray
Subscribe for More Information
07:37 EDTCELGCelgene reports Q2 Revlimid sales up 19% to $1.44B
ABRAXANE® sales for the second quarter were $244 million, a 13 percent increase. POMALYST®/IMNOVID® sales for the second quarter were $235 million, an increase of 46%. VIDAZA® sales in the second quarter remained flat year-over-year at $152 million. OTEZLA® sales for the second quarter were $90 million, increasing 49 percent over the first quarter of 2015.
07:37 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
07:32 EDTCELGCelgene reports Q2 adjusted EPS $1.23, consensus $1.20
Subscribe for More Information
July 22, 2015
15:26 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
09:28 EDTCELGBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
11:03 EDTCELGCelgene treatment of pediatric Crohn's disease receives FDA orphan designation
Subscribe for More Information
06:29 EDTCELGCelgene price target raised to $160 from $147 at Piper Jaffray
Subscribe for More Information
06:24 EDTCELGPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use